{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-057132","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.096212+00:00","generated_at":"2026-06-13T08:27:55.080537+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics closes $7.5 million private placement of common stock and warrants","bullets":["Closed offering of 4,285,715 shares (or pre-funded warrants) at $1.75 per share, raising ~$7.5M gross.","Issued warrants to purchase 4,285,715 shares at $1.75, exercisable for 5.5 years from issuance.","Net proceeds to be used for working capital to advance tecarfarin development.","Directors and officers subject to 60-day lock-up after registration statement effectiveness.","Placement agent H.C. Wainwright; Boustead Securities acted as financial advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-057132","json":"https://secwatch.observer/filing/0001213900-23-057132.json","markdown":"https://secwatch.observer/filing/0001213900-23-057132.md","text":"https://secwatch.observer/filing/0001213900-23-057132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/ea181825-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:27:55.080537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2464c3fbf71aeaaa5c19219935f3776d5e16b896","claim":"Cadrenal Therapeutics, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2023-07-12).","evidence_excerpt":"Pursuant to a letter agreement dated July 12, 2023 (the “Engagement Agreement”), H.C. Wainwright & Co., LLC (“HWC”) acted as placement agent for the Private Placement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2023-07-12"}],"fact_type":"material_agreement"},{"claim_id":"8086a56822603ba7410ca2110e4e0aed8441a885","claim":"Cadrenal Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2023-07-12).","evidence_excerpt":"In connection with the Private Placement, the Company has entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, dated July 12, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Investor"},{"label":"Effective","value":"2023-07-12"}],"fact_type":"material_agreement"},{"claim_id":"94efe292cf446b214cae009d0420470e235be3fd","claim":"Cadrenal Therapeutics, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $7.5 million (effective 2023-07-12).","evidence_excerpt":"On July 12, 2023, Cadrenal Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023057132/0001213900-23-057132-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional accredited investor"},{"label":"Value","value":"approximately $7.5 million"},{"label":"Effective","value":"2023-07-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}